As discussed previously, the most frequently used targeted therapies for HCC, such as sorafenib, are selective inhibitors of the immunological checkpoint protein programmed death receptor-1 (PD-1, encoded by PDCD1 (Palamarchuk et al., 2022). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.